NeoGenomics, Inc. | Stephens

Who We Are

What We Do

We provide investment banking, research, sales and trading, asset and wealth management, public finance, insurance, private capital, and family office services.

About Us

We are a family-owned financial services firm that values client relationships, long-term stability, and supporting the communities where we live and work.

The Stephens Story

The idea of family defines our culture, because each of us knows that our reputation is on the line as if our own name was on the door.


Our reputation as a leading independent financial services firm is built on the stability of our longstanding and highly experienced senior executives.

Impact Initiatives

We are committed to corporate philanthropy; economic and financial literacy advocacy; and diversity, equity, and inclusion initiatives.

Our Brand Ambassadors

Stephens is proud to sponsor the PGA TOUR, LPGA Tour, and PGA TOUR Champions careers, as well as applaud the philanthropic endeavors, of our Brand Ambassadors.

Making Connections

We host many highly informative meetings each year with clients, industry decision makers, and thought leaders across the U.S. and in Europe.

Back to transactions
Sole Placement Agent

NeoGenomics, Inc.

$80 Million 12/30/2015 Healthcare Services Complete
Lead Bankers: Shawn Fitz, A. Davidson Hall
Public Companies
Show Tombstone

Transaction Details

  • On December 30, 2015, NeoGenomics, Inc. (NASDAQ: NEO or the “Company”), a leading provider of cancer-focused genetic testing services, acquired Clarient Diagnostics Services, Inc. (“Clarient”), a similar business and former operating subsidiary of GE Healthcare’s Life Sciences business
  • Stephens Inc. served as sole placement agent to NeoGenomics in the transaction successfully raising $80mm of committed, fully underwritten debt financing to support NEO’s acquisition of Clarient

Under the terms of the agreement, NEO has acquired Clarient via:

  • $80mm in cash
  • $110mm in preferred stock
  • 15mm shares of NeoGenomics’ common stock

The cash component of the purchase price was funded via:

  • Existing cash from NEO’s balance sheet
  • New, 5-year, $25mm Senior Secured ABL Revolver provided by Wells Fargo
  • New, 5-year, $55mm Senior Secured Term Loan provided by AB Private Credit Investors (an affiliate of Alliance Bernstein)

About the company

NeoGenomics, Inc.

NeoGenomics, Inc. provides specialized and comprehensive cancer genetic testing services through its network of CLIA-certified clinical laboratories. The Company's advanced testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, digital and anatomic pathology and molecular genetic testing. NeoGenomics services the needs of pathologists, oncologists, other clinicians and hospitals throughout the United States, and also provides clinical trial support services to the Pharmaceutical industry. The company has laboratories in Nashville, TN; Aliso Viejo, Irvine, Fresno and West Sacramento, CA; Houston, TX; and Tampa and Fort Myers, FL. For additional information about NeoGenomics, visit

Clarient Diagnostics Services, Inc.

Clarient Diagnostics Services, Inc. is a provider of comprehensive cancer diagnositc testing to hospitals, physicians and the pharmaceutical industry and was a unit of GE Healthcare’s Life Sciences business. Clarient is based in Aliso Viejo, California and Houston, Texas. Clarient has approximately 415 employees and reported 2014 revenue of approximately $127mm. For additional information about Clarient, visit http://clarient.gehealthcare.c....

Sources: Company filings and publicly available information.
  1. This material has been prepared solely for informative purposes as of its stated date and is not a solicitation, or an offer, to buy or sell any security. It does not purport to be a complete description of the securities, markets or developments referred to in the material. Information included in the material was obtained from external sources which we consider reliable, but we have not independently verified such information and do not guarantee that it is accurate or complete. Such information is believed to be accurate on the date of issuance of the material. No subsequent publication or distribution of this material shall mean or imply that any such information or opinion remains current at any time after the stated date of the material. We do not undertake to advise you of any changes in any such information or opinion. Additional information is available upon request.